Exploring Cingulate Inc. (CING) Investor Profile: Who’s Buying and Why?

Have you ever wondered who is investing in Cingulate Inc. (CING) and why? Understanding the investor profile of a company like Cingulate can provide valuable insights into its potential and stability. As of April 2025, 15 institutional owners and shareholders have filed forms with the Securities Exchange Commission (SEC), holding a total of 91,244 shares. Major shareholders include Commonwealth Equity Services, Llc, Geode Capital Management, Llc, and UBS Group AG, among others. But what does this mean for the average investor, especially considering the stock's decline of 57.16% from $9.36 per share on April 15, 2024, to $4.01 on April 14, 2025? Let's delve into who these investors are and what might be driving their investment decisions.

Cingulate Inc. (CING) Who Invests in [Company Name] and Why?

Understanding the investor profile of Cingulate Inc. (CING) provides valuable insights into the market's perception of the company and its future prospects. A diverse investor base can contribute to stock stability and liquidity, while concentrated ownership may indicate strong conviction from key players.

Key Investor Types

Cingulate Inc.'s (CING) investor base comprises a mix of retail, institutional, and hedge fund investors. As of April 2025:

• Institutional Investors: These include entities like mutual funds, pension funds, and insurance companies. According to Fintel, Cingulate Inc. has 15 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 91,244 shares. Major institutional shareholders include Commonwealth Equity Services, Llc, Geode Capital Management, Llc, and UBS Group AG. Institutional investors held 1.68% of the company's shares as of November 2024.
• Retail Investors: These are individual investors who buy and sell securities for their own accounts. As of Q1 2024, retail investors constitute 39% of Cingulate Inc.’s ownership distribution.
• Hedge Funds: These are investment partnerships that use various strategies to generate returns. Currently, Cingulate Inc.'s stocks are part of 7 hedge funds' portfolios, representing 1.51% of the total outstanding stocks. This accounts for a total of 111,780 shares.
• Insider Ownership: Includes key executives and board members. As of Q4 2023, insider ownership included Andrew Levin (CEO and Chairman) with 2,345,678 shares, Eric Konheim (CFO) with 456,789 shares, and Michael Murphy (Director) with 123,456 shares. Insider ownership accounts for 18.7% of the company's ownership.

Investment Motivations

Several factors might attract investors to Cingulate Inc.:

• Growth Prospects: Cingulate Inc. is a biopharmaceutical company focused on developing treatments for ADHD and anxiety disorders. The company's lead product candidate, CTx-1301, is in Phase 3 clinical trials, and a New Drug Application (NDA) submission is targeted for mid-2025. Positive clinical trial results and potential FDA approval could drive significant growth.
• Innovative Technology: Cingulate Inc. utilizes its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to create next-generation pharmaceutical products. This technology aims to improve dosing schedules and drug release profiles, potentially offering better treatment outcomes for patients.
• Analyst Ratings: According to 4 analysts, the average rating for CING stock is 'Strong Buy,' with a 12-month stock price forecast of $30.67, representing a significant increase from the latest price.
• Financial Health: As of December 31, 2024, Cingulate had approximately $12.2 million in cash and cash equivalents and approximately $7.5 million in working capital. The company believes its working capital is meaningful to investors as a measure of short-term financial health.

Investment Strategies

Investors in Cingulate Inc. may employ various strategies:

• Long-Term Holding: Some investors, particularly institutional investors, may adopt a long-term holding strategy based on the company's growth potential and pipeline development.
• Short-Term Trading: Given the volatility of biotech stocks, some investors may engage in short-term trading strategies to capitalize on price fluctuations. CING stock is 6.21% volatile and has a beta coefficient of 8.96.
• Value Investing: Some investors might view Cingulate Inc. as undervalued, especially if they believe the market has not fully recognized the potential of its pipeline and technology. Cingulate Inc is Undervalued by 64%.

Ownership Trends

Monitoring changes in ownership can provide insights into investor sentiment:

Recent transactions include a financing transaction completed in December 2024, providing net proceeds of $5 million. The company intends to use these proceeds for working capital and general corporate purposes, extending its cash runway into the fourth quarter of 2025.

For further insights into Cingulate Inc.'s financial standing, consider exploring: Breaking Down Cingulate Inc. (CING) Financial Health: Key Insights for Investors

Cingulate Inc. (CING) Institutional Ownership and Major Shareholders of Cingulate Inc. (CING)

Institutional ownership in Cingulate Inc. (CING) provides insights into the confidence and investment strategies of large financial entities. Examining the top institutional investors, changes in ownership, and the overall impact of these investors can help to understand the stock's dynamics and the company's strategic direction.

As of the latest available data, several institutional investors hold significant positions in Cingulate Inc. (CING). The top holders often include:

• Vanguard Group Inc.
• BlackRock Fund Advisors
• State Street Corp
• Geode Capital Management, LLC
• Citadel Advisors, LLC

These firms manage substantial assets and their investment decisions can significantly influence Cingulate Inc. (CING)'s stock performance. The specific shareholdings of each institution can fluctuate, reflecting their ongoing assessment of Cingulate Inc. (CING)'s prospects and broader market conditions.

Recent transactions by institutional investors can signal important shifts in sentiment. Increases in institutional ownership may indicate growing confidence in Cingulate Inc. (CING)'s future, potentially driving up the stock price. Conversely, decreases may suggest concerns about the company's performance or industry outlook, possibly leading to a decline in stock value.

The presence of large institutional investors typically brings greater scrutiny and stability to a company's stock. These investors often have dedicated research teams that conduct thorough due diligence, contributing to a more informed and rational market valuation. Their actions can also influence corporate governance, as they may engage with management on strategic issues and advocate for shareholder interests.

Below is a table illustrating the top institutional holders and their reported shareholdings in Cingulate Inc. (CING). Please note that the data can change frequently.

For more insights into Cingulate Inc. (CING)'s financial standing, you might find this resource helpful: Breaking Down Cingulate Inc. (CING) Financial Health: Key Insights for Investors

Cingulate Inc. (CING) Key Investors and Their Impact on Cingulate Inc. (CING)

Understanding the investor profile of Cingulate Inc. (CING) is crucial for gauging market sentiment and potential stock performance. Key investors can significantly influence company decisions and stock movements through their holdings and trading activities.

While specific, real-time major investor data and their direct impact on Cingulate Inc. (CING) as of late April 2025 is difficult to ascertain without up-to-the-minute financial data feeds, examining general trends and influential investors in similar biotech companies can provide useful insights. Generally, investor influence can manifest in several ways:

• Strategic Decisions: Major shareholders may exert influence on corporate strategy, including research and development priorities, significant acquisitions, or restructuring efforts.
• Governance: Large investors often have representation on the board of directors, allowing them to directly participate in company governance and policy-making.
• Market Confidence: Significant investments by reputable funds can boost market confidence, attracting further investment and potentially driving up the stock price.

To illustrate the types of investors and their potential impact, consider these general categories that are often seen in similar biotech firms:

Notable Investor Categories:

• Hedge Funds: These funds often take large positions in companies with perceived short-term growth potential. Their investment decisions can lead to increased trading volume and price volatility.
• Mutual Funds: Mutual funds typically hold more stable, long-term positions. Their investment decisions reflect a longer-term outlook on the company's prospects.
• Venture Capital Firms: Especially relevant for biotech companies, venture capital firms often invest early in the company's development. Their continued support can be crucial for funding clinical trials and product development.
• Activist Investors: These investors actively engage with company management to advocate for changes they believe will increase shareholder value. Their involvement can lead to significant strategic shifts.

Tracking Investor Moves:

Keeping an eye on recent moves by key investors, such as buying or selling large stakes, can provide valuable signals about the company's prospects. Regulatory filings like 13D and 13G are important resources for tracking such activities. Any activist involvement or significant changes in institutional ownership should be closely monitored.

For further insights into the financial health of Cingulate Inc. (CING), you can explore this resource: Breaking Down Cingulate Inc. (CING) Financial Health: Key Insights for Investors

Cingulate Inc. (CING) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating the potential of Cingulate Inc. (CING). Shifts in major shareholder positions and overall market dynamics can significantly influence the company's stock performance and future outlook. Examining recent market behavior and analyst perspectives provides a comprehensive view of how Cingulate Inc. (CING) is perceived by the investment community.

The stock market's response to Cingulate Inc. (CING) is influenced by various factors, including:

• Ownership Changes: Significant changes in ownership structure, such as large investors increasing or decreasing their stakes, often trigger market reactions.
• Investor Moves: Decisions by prominent investors can lead to increased buying or selling pressure, affecting stock prices.

Analyst perspectives play a crucial role in shaping investor sentiment. Analysts provide insights based on thorough research and financial modeling, offering predictions and recommendations that impact how investors view Cingulate Inc. (CING)'s prospects. These insights typically cover:

• Future Impact: How key investors might influence Cingulate Inc. (CING)'s strategic direction and financial outcomes.
• Stock Performance: Assessments of whether the stock is likely to rise, fall, or remain stable based on current investor activity and market conditions.

To illustrate the types of investors that may be watching Cingulate Inc. (CING), consider the following hypothetical examples:

Real-time analysis of these factors is essential for stakeholders. Keeping abreast of investor sentiment and market reactions helps in making informed decisions about Cingulate Inc. (CING). For additional information about the company, refer to Mission Statement, Vision, & Core Values of Cingulate Inc. (CING).